Overview

The use of digital strategies to systematically monitor patients' symptoms in clinical settings allows problems to be detected at an early stage before they worsen or lead to complications. In this study, the hypothesis is that the proportion of patients with a weight loss of at least 5% between before radiotherapy/radiochemotherapy and 3 months after treatment would be lower with optimised care thanks to remote monitoring using a medical telemonitoring solution in oncology.

Eligibility

Inclusion Criteria:

• Patient aged over 18 and under 75 years WHO score \< 2,
  • Treated for localised heand and neck cancer of the squamous cell carcinoma type for which curative treatment has been chosen and receiving radiotherapy or radio-chemotherapy exclusively or as an adjuvant with the aim of cure
  • Having signed the informed consent form,
  • Affiliated with or beneficiary of a social protection scheme,
  • Access to a smartphone or the internet,

Exclusion Criteria:

• History of other neoplastic disease less than 2 years ago or progressive disease,
• History of ENT radiotherapy,
• Pregnant or breastfeeding women,
• Protected adults (under guardianship, curatorship or judicial protection),
• Patients participating in a therapeutic study,
• Patients unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological or geographical issues, etc.), patients with blindness preventing the use of the medical telemonitoring solution in oncology.